Skip to main content
SpringerLink
Log in

Percutaneous Fluoroscopic-Guided Endomyocardial Delivery in an Experimental Model of Left Ventricular Assist Device Support

  • Published:
Journal of Cardiovascular Translational Research Aims and scope Submit manuscript

Abstract

Endomyocardial delivery in the setting of active left ventricular assist device (LVAD) support has rarely been studied. The objective was to establish a protocol for endomyocardial injections during LVAD support without compromising mechanical circulation. LVAD implantation was performed in four pigs. A curved needle catheter was percutaneously inserted into the right carotid artery and positioned into the left ventricle under fluoroscopic guidance. In the setting of increasing LVAD flows (2.3–3.1 l/min), percutaneous methylene blue dye administration into the myocardium proceeded without complications in all pigs. Transection of excised hearts revealed an anterior, lateral, inferior, and septal wall distribution of methylene blue documenting injections in all four regions of the left ventricle. Ex vivo, the catheter could be maneuvered close to the LVAD inflow cannula despite augmentation of LVAD flow up to 5 l/min. Endomyocardial injections during LVAD support was found to be feasible and safe with the curved needle catheter.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Abbreviations

LVAD:

Left ventricular assist device

References

  1. Mosterd, A., & Hoes, A. W. (2007). Clinical epidemiology of heart failure. Heart, 93, 1137–1146.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Redfield, M. M., Jacobsen, S. J., Burnett, J. C., Jr., et al. (2003). Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA, 289, 194–202.

    Article  PubMed  Google Scholar 

  3. Slaughter, M. S., Rogers, J. G., Milano, C. A., Russel, S. D., Conte, J. V., Feldman, D., et al. (2009). Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl Med, 361, 2241–2251.

    Article  CAS  Google Scholar 

  4. Birks, E. J. (2013). Molecular changes after left ventricular assist device support for heart failure. Circulation Research, 113, 777–791.

    Article  CAS  PubMed  Google Scholar 

  5. Hall, J. L., Fermin, D. R., Birks, E. J., Barton, P. J., Slaughter, M., & Eckman, P. (2011). Clinical, molecular, and genomic changes in response to a left ventricular assist device. Journal of the American College of Cardiology, 57, 641–652.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Behfar, A., Crespo-Diaz, R., Terzic, A., & Gersh, B. J. (2014). Cell therapy for cardiac repair—lessons from clinical trials. Nature Reviews Cardiology, 11, 232–246.

    Article  PubMed  Google Scholar 

  7. Ibrahim, M., & Yacoub, M. H. (2014). Bridge to recovery and weaning protocols. Heart Failure Clinics, 10, S47–S55.

    Article  PubMed  Google Scholar 

  8. Anastasiadis, K., Antonitsis, P., Argiriadou, H., Koliakos, G., Doumas, A., Khayat, A., et al. (2011). Hybrid approach of ventricular assist device and autologous bone marrow stem cells implantation in end-stage ischemic heart failure enhances myocardial reperfusion. Journal of Translational Medicine, 9, 12.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Ascheim, D. D., Gelijns, A. C., Goldstein, D., Moye, L. A., Smedira, N., Lee, S., et al. (2014). Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices. Circulation, 129, 2287–2296.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Zheng, Y., Sampaio, L. C., Li, K., Silva, G. V., Cabreira-Hansen, M., Vela, D., et al. (2013). Safety and feasibility of mapping and stem cell delivery in the presence of an implanted left ventricular assist device: a preclinical investigation in sheep. Texas Heart Institute Journal, 40, 229–234.

    PubMed Central  PubMed  Google Scholar 

  11. Behfar, A., Latere, J. P., Bartunek, J., Homsy, C., Daro, D., Crespo-Diaz, R. J., et al. (2013). Optimized delivery system achieves enhanced endomyocardial stem cell retention. Circulation. Cardiovascular Interventions, 6, 708–710.

    Article  Google Scholar 

  12. Vikholm, P., Schiller, P., Johansson, J., & Hellgren, L. (2014). Cavoaortic shunt improves hemodynamics with preserved oxygen delivery in experimental right ventricular failure during left ventricular assist device therapy. Journal of Thoracic and Cardiovascular Surgery, 147, 625–631.

    Article  PubMed  Google Scholar 

  13. Nakamuta, J. S., Danoviz, M. E., Marques, F. L., dos Santos, L., Becker, C., Gonçalves, G. A., et al. (2009). Cell therapy attenuates cardiac dysfunction post myocardial infarction: effect of timing, routes of injection and a fibrin scaffold. PLoS One, 4, e6005.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Telukuntla, K. S., Suncion, V. Y., Schulman, I. H., & Hare, J. M. (2013). The advancing field of cell-based therapy: insights and lessons from clinical trials. J Am Heart Assoc, 2, e000338.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Andreas Rück, MD, PhD at the Department of Cardiology at Karolinska University Hospital for the technical support and Tor Kristoffersen, Innova Medical AS, for providing the HeartWare LVAD system for experimental use.

Sources of Funding

This study was supported in part by grants from the Karolinska Institutet, Stockholm County Council Strategic Grants, the Swedish Heart-Lung Foundation, the Mats Kleberg Foundation, Mayo Clinic Center for Regenerative Medicine, Marriott Foundation, Michael S. and Mary Sue Shannon Family, and Russ and Kathy VanCleve Foundation.

Conflict of Interest

Aymeric Seron and Warren Sherman are affiliated with Celyad S.A.

Statement on the Welfare of Animals

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the Uppsala Ethical Committee of Animal Research.

Author information

Authors and Affiliations

  1. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden

    Magnus Dalén & Karl-Henrik Grinnemo

  2. Department of Cardiothoracic Surgery and Anesthesiology, Karolinska University Hospital, Stockholm, Sweden

    Magnus Dalén & Karl-Henrik Grinnemo

  3. Division of Cardiovascular Diseases and Center for Regenerative Medicine, Mayo Clinic, Rochester, MN, USA

    Atta Behfar & Andre Terzic

  4. Department of Cardiothoracic Surgery, Uppsala University Hospital, Uppsala, Sweden

    Petter Schiller

  5. Celyad S.A., Mont-Saint-Guibert, Belgium

    Aymeric Seron & Warren Sherman

  6. Department of Medicine, Division of Cardiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

    Agneta Månsson-Broberg

  7. Center for Diseases of Aging at Vaccine and Gene Therapy Institute, Port St. Lucie, FL, USA

    Karl-Henrik Grinnemo

Authors
  1. Magnus Dalén
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Atta Behfar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andre Terzic
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Petter Schiller
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aymeric Seron
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Warren Sherman
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Agneta Månsson-Broberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Karl-Henrik Grinnemo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Magnus Dalén.

Additional information

Associate Editor Lorrie Kirshenbaum oversaw the review of this article

Electronic supplementary material

Below is the link to the electronic supplementary material.

Animation of the curved needle catheter. (MP4 38816 kb)

Methylene blue dye administered percutaneously into the endocardium and myocardium using the curved needle catheter during step-wise increased LVAD flow and fluoroscopic guidance. (M4V 9087 kb)

In vitro study with the LVAD run in buffered glucose solution carrier. The catheter is easily maneuvered close to the LVAD inflow cannula during a LVAD estimated flow of 5 L/min. (MOV 19975 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dalén, M., Behfar, A., Terzic, A. et al. Percutaneous Fluoroscopic-Guided Endomyocardial Delivery in an Experimental Model of Left Ventricular Assist Device Support. J. of Cardiovasc. Trans. Res. 8, 381–384 (2015). https://doi.org/10.1007/s12265-015-9642-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12265-015-9642-4

Keywords

Search

Navigation